Cargando...
Emerging treatment options for patients with high-risk myelodysplastic syndrome
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...
Guardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675905/ https://ncbi.nlm.nih.gov/pubmed/33240476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720955006 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|